Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Mapping Immune Escape in Lymphoma and Overcoming It with Novel Optimized Multispecific Antibodies

Objetivo

Novel immunotherapies, such as bispecific antibodies (BiAbs), have transformed lymphoma treatment. Although biAbs are currently mostly used in later lines, their efficacy and scalability are expected to establish them as a major component of first-line treatment. However, relapse and refractory disease remain common during biAb therapy. Modes of escape are not clearly defined, comprehensive analyses of the surfaceome are lacking, and clinical biAbs are currently limited to CD3×CD20. Multispecific antibodies (msAbs) that can target more than two antigens and engage additional effector cells could overcome the limitations of current biAbs.
To this end, we will map biAb escape in patients and use these insights to guide the development of novel, optimised msAbs, with the ultimate aim of improving lymphoma therapy. In Aim 1, we will define resistance at the surfaceome level in biosamples from a longitudinal cohort by integrating molecular surfaceome profiling with mechanistic validation in ex vivo killing assays. In Aim 2, we will establish and refine an msAb pipeline to enable the rapid design, production and testing of msAbs. As an initial proof of concept, we will prioritise msAbs that engage NK cells, as this is an under-explored effector route in lymphoma. Using the resistance map from Aim 1, we will then design msAbs that specifically overcome biAb escape. In Aim 3, we will evaluate lead candidates using patient-derived organoids and humanised lymphoma mouse models, with the aim of identifying constructs for further development. My group and I are well placed to fulfil all aims and lead the project to success, leveraging our extensive experience in clinical haematology and in-depth knowledge of human antibody engineering.
In conclusion, our project will improve understanding of biAb resistance and escape and deliver novel, optimised msAbs that are highly effective, limit escape and have favourable safety profiles, thereby significantly advancing lymphoma therapy.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-ERC - HORIZON ERC Grants

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) ERC-2026-STG

Ver todos los proyectos financiados en el marco de esta convocatoria

Institución de acogida

KLINIKUM DER UNIVERSITAET ZU KOELN
Aportación neta de la UEn
€ 1 499 100,00
Dirección
Kerpener Strasse 62
50937 Koeln
Alemania
Región
Nordrhein-Westfalen Köln Köln, Kreisfreie Stadt
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 1 499 100,00

Beneficiarios (1)